A new murine IgG1 anti-Tn monoclonal antibody with in vivo anti tumour activity.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

A new murine IgG1 anti-Tn monoclonal antibody with in vivo anti tumour activity. / Welinder, Charlotte; Baldetorp, Bo; Borrebaeck, Carl; Fredlund, Britt-Marie; Jansson, Bo.

I: Glycobiology, Vol. 21, Nr. 8, 2011, s. 1097-1107.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

APA

CBE

MLA

Vancouver

Author

RIS

TY - JOUR

T1 - A new murine IgG1 anti-Tn monoclonal antibody with in vivo anti tumour activity.

AU - Welinder, Charlotte

AU - Baldetorp, Bo

AU - Borrebaeck, Carl

AU - Fredlund, Britt-Marie

AU - Jansson, Bo

PY - 2011

Y1 - 2011

N2 - The Tn antigen (GalNAc alpha-O-Ser/Thr) is heterogeneously synthesised by a variety of tumours and contains an epitope defined by lectins and antibodies as a cluster of alpha GalNAc carbohydrates synthesised within a peptide sequence, which is rich in serine and/or threonine. The Tn antigen has been utilized as a target in vaccine experiments and also used as a biomarker for prognosis of different cancer forms. In this paper we present a new monoclonal antibody, GOD3-2C4, with the clear hallmarks of an anti-Tn antibody. It was generated through somatic cell hybridisation after immunisation of a mouse with a tumour cell line and a Tn carrying mucin. The antibody recognises synthetic Tn antigen and binds breast, colon, lung, ovarian and pancreas cancer. The GOD3-2C4 antibody has ADCC activity against Jurkat cells in vitro and for the first time it can be shown that an anti-Tn antibody has a significant in vivo effect on a human cancer cell line grown as a xenograft in SCID mice.

AB - The Tn antigen (GalNAc alpha-O-Ser/Thr) is heterogeneously synthesised by a variety of tumours and contains an epitope defined by lectins and antibodies as a cluster of alpha GalNAc carbohydrates synthesised within a peptide sequence, which is rich in serine and/or threonine. The Tn antigen has been utilized as a target in vaccine experiments and also used as a biomarker for prognosis of different cancer forms. In this paper we present a new monoclonal antibody, GOD3-2C4, with the clear hallmarks of an anti-Tn antibody. It was generated through somatic cell hybridisation after immunisation of a mouse with a tumour cell line and a Tn carrying mucin. The antibody recognises synthetic Tn antigen and binds breast, colon, lung, ovarian and pancreas cancer. The GOD3-2C4 antibody has ADCC activity against Jurkat cells in vitro and for the first time it can be shown that an anti-Tn antibody has a significant in vivo effect on a human cancer cell line grown as a xenograft in SCID mice.

KW - monoclonal antibody

KW - in vivo therapy

KW - antigen

KW - Tn

KW - anti-carbohydrate

KW - biomarker

U2 - 10.1093/glycob/cwr048

DO - 10.1093/glycob/cwr048

M3 - Article

C2 - 21470982

VL - 21

SP - 1097

EP - 1107

JO - Glycobiology

JF - Glycobiology

SN - 1460-2423

IS - 8

ER -